Acurx Pharmaceuticals (ACXP) Share-based Compensation (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Share-based Compensation for 7 consecutive years, with $719063.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 121.79% year-over-year to $719063.0; the trailing twelve-month figure through Jun 2026 stood at $719063.0 (down 67.31% YoY), and the FY2025 full-year result was $1.2 million, down 52.06% from the prior year.
• Share-based Compensation grew to $719063.0 in Q2 2026 per ACXP's latest filing, from $258287.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.6 million in Q2 2022 and bottomed at $258287.0 in Q1 2026.
• Historically, Share-based Compensation has averaged $2.4 million across 5 years, with a median of $2.1 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation soared 899.82% in 2022, then sank 94.33% in 2026.
• Over 5 years, Share-based Compensation stood at $696965.0 in 2022, then rose by 19.56% to $833285.0 in 2023, then tumbled by 58.57% to $345191.0 in 2024, then decreased by 14.6% to $294794.0 in 2025, then jumped by 143.92% to $719063.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $719063.0, $258287.0, and $294794.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.